Showing 21-30 of 3001 results for "".
- Defining the Spectrum of MS Treatment Goalshttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN0106mstreatmentgoals-pdf/31355/Evolving Outcome Measures and Therapeutic Developments in Multiple SclerosisNathan Hall’s article in the January 2006 issue of *Practical Neurology* provides a comprehensive overview of the evolving landscape of outcome measures and treatment strategies in multiple sclerosis (MS). As MS research adv
- MS Diagnosis: Sizing Up the Suspectshttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/pn0205pg52-56-pdf/31493/Diagnosing multiple sclerosis (MS) remains one of the most challenging tasks in neurology due to its diverse clinical presentations and numerous mimicking conditions. In Jeffrey I. Greenstein’s February 2005 article in *Practical Neurology*, the complexities of differentiating MS from other neurolog
- What to Expect When the MS Patient is Expectinghttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN0708MSPregFea-pdf/31007/Multiple sclerosis (MS) typically manifests in individuals during their late 20s, with an average onset age of 28 for women and early 30s for men. Relapsing-remitting MS is the most prevalent form, predominantly affecting females, while primary progressive MS shows equal incidence across genders. Re
Patients Report Delays in MS Diagnosis, High Interest in Oral Therapy
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/patients-report-delays-in-ms-diagnosis-high-interest-in-oral-therapy/30673/Nationwide survey provides a snapshot of “MS in America.”- Bad Reception: When MS Patients Are on a Different Wavelengthhttps://practicalneurology.com/columns/practice-management/bad-reception-when-ms-patients-are-on-a-different-wavelength/31064/Enhancing Physician-Patient Relationships to Improve MS Patient RetentionMaintaining strong physician-patient alliances is crucial in managing Multiple Sclerosis (MS), a chronic and unpredictable neurological disorder. According to a January 2008 article in Practical Neurology, MS patients frequentl
The Changing World of MS
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PN0209_03-php/30946/A new study has attempted to establish the global epidemiology of MS at every corner of the globe. Do your assumptions match emerging realities?Oral Disease Modifying Therapy for MS: Important Considerations
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/oral-disease-modifying-therapy-for-ms-important-considerations/30827/The availability of an oral agent for MS may create a therapeutic dilemma for clinicians as they try to determine the role of new therapy in patient care.- Identifying Neurobehavioral Changes in MS Patientshttps://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/PD0806ChangesInMSfea-pdf/31278/Neurobehavioral Changes in Multiple Sclerosis: A Comprehensive OverviewMultiple sclerosis (MS) is traditionally recognized for its neuromuscular symptoms; however, recent research underscores significant neurobehavioral alterations, including cognitive impairments and neuropsychiatric disorders. Cog
MS Minute: Multiple Sclerosis & the Gut Microbiome
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-multiple-sclerosis-the-gut-microbiome/31927/The gut microbiome and its relationship with MS is an exciting and active area of research with much promise and much to be elucidated.Pathway to Success? MS Drug Takes Nrf-2 Pathway for Treatment
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/pathway-to-success-ms-drug-takes-nrf-2-pathway-for-treatment/30774/BG-12 is an oral therapy under regulatory review in the US and Europe for the treatment of MS.